Note: This document contains side effect information about atezolizumab. Some dosage forms listed on this page may not apply to the brand name Tecentriq.
Summary
Common side effects of Tecentriq include: herpes simplex encephalitis, infection, mycobacterium infection, retroperitoneal hemorrhage, sepsis, severe infection, urinary tract infection, colitis, diarrhea, and increased thyroid stimulating hormone level. Continue reading for a comprehensive list of adverse effects.
Applies to atezolizumab: parenteral injection.
Side effects include:
Single-agent atezolizumab (the active ingredient contained in Tecentriq) (≥20%): Fatigue or asthenia, nausea, cough, dyspnea, decreased appetite.
In combination with other antineoplastic agents in patients with NSCLC or SCLC (≥20%): Fatigue or asthenia, nausea, alopecia, constipation, diarrhea, decreased appetite.
In combination with albumin-bound paclitaxel in patients with triple-negative breast cancer (≥20%): Alopecia, peripheral neuropathy, fatigue, nausea, diarrhea, constipation, cough, headache, vomiting, decreased appetite; laboratory abnormalities occurring in ≥50% of patients include decreased concentrations of hemoglobin, leukocytes, neutrophils, and lymphocytes.
In combination with bevacizumab in patients with HCC (≥20%): Hypertension, fatigue, proteinuria.
In combination with cobimetinib and vemurafenib in patients with melanoma (≥20%): Rash, musculoskeletal pain, fatigue, hepatotoxicity, pyrexia, nausea, pruritus, edema, stomatitis, hypothyroidism, photosensitivity.
For Healthcare Professionals
Applies to atezolizumab: intravenous solution.
Cardiovascular
Common (1% to 10%): Venous thromboembolism[Ref]
Dermatologic
Very common (10% or more): Rash (15%), pruritus (13%)[Ref]
Endocrine
Frequency not reported: Immune-related thyroid disorders (e.g., hyperthyroidism, hypothyroidism)[Ref]
Gastrointestinal
Very common (10% or more): Nausea (25%), constipation (21%), diarrhea (18%), abdominal pain (17%), vomiting (17%)
Common (1% to 10%): Dehydration, intestinal obstruction[Ref]
General
The most common adverse reactions (greater than 20%) were fatigue, decreased appetite, nausea, urinary tract infection, pyrexia, and constipation. The most common Grade 3 to 4 adverse reactions (greater than 2%) were urinary tract infection, anemia, fatigue, dehydration, intestinal obstruction, urinary obstruction, hematuria, dyspnea, acute kidney injury, abdominal pain, venous thromboembolism, sepsis, and pneumonia.[Ref]
Genitourinary
Very common (10% or more): Urinary tract infection (22%)
Common (1% to 10%): Urinary obstruction[Ref]
Hematologic
Common (1% to 10%): Anemia, lymphopenia, increased alkaline phosphatase, increased alkaline phosphatase[Ref]
Hepatic
Common (1% to 10%): Acute kidney injury, liver enzyme increase, increased ALT, increased AST
Immunologic
Very common (10% or more): Immune related colitis (19.7%)
Common (1% to 10%): Immune related pneumonitis, immune related hepatitis, sepsis
Frequency not reported: Immune related endocrinopathies[Ref]
Local
Frequency not reported: Infusion related reactions[Ref]
Metabolic
Very common (10% or more): Decreased appetite (26%)
Common (1% to 10%): Hyponatremia, hyperglycemia, hypoalbuminemia[Ref]
Musculoskeletal
Very common (10% or more): Back/neck pain (15%), arthralgia (14%)[Ref]
Nervous system
Frequency not reported: Meningoencephalitis, myasthenic syndrome/myasthenia gravis, Guillain-Barre[Ref]
Ocular
Frequency not reported: Ocular inflammatory toxicity[Ref]
Other
Very common (10% or more): Fatigue (52%), pyrexia (21%), peripheral edema (18%)
Common (1% to 10%): Increased creatinine[Ref]
Psychiatric
Common (1% to 10%): Confusional state[Ref]
Renal
Common (1% to 10%): Hematuria[Ref]
Respiratory
Very common (10% or more): Dyspnea (16%), cough (14%)
Common (1% to 10%): Dyspnea, pneumonia[Ref]
